10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 701–800 of 1,169
Bakris, G. L. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0713 · Cited by 145
“001).(56) Intensive glucose control (HbA 1c 6.”
Yamagishi, S., Fukami, K., & Matsui, T. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0176-5 · Cited by 135
“Furthermore, a follow-up study of United Kingdom Prospective Diabetes Study (UKPDS), called UKPDS80, has also shown that benefits of an intensive therapy in patients with type 2 diabetes are sustained after the cessation of the trial [20].”
BackgroundAnalysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications
Gupta, S., Maratha, A., Siednienko, J., Natarajan, A., Gajanayake, T., Hoashi, S., & Miggin, S. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-07230-8 · Cited by 132
The promise and peril of universal health care
Bloom, D. E., Khoury, A. F., & Subbaraman, R. (2018) · Science · doi:10.1126/science.aat9644 · Cited by 146
Juarez, D. T., Sentell, T., Tokumaru, S., Goo, R., Davis, J. W., & Mau, M. M. (2012) · Preventing Chronic Disease · doi:10.5888/pcd9.120065 · Cited by 122
Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta‐Analysis
Mitsios, J. P., Ekinci, E. I., Mitsios, G. P., Churilov, L., & Thijs, V. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007858 · Cited by 116
“Four studies [5-8] presented dichotomised HbA1c categorical data.”
BackgroundDiagnosing and managing diabetes in HIV-infected patients: current concepts
Monroe, A. K., Glesby, M. J., & Brown, T. T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu779 · Cited by 125
“Achieving glycemic targets has been shown to decrease microvascular (retinopathy, neuropathy, and nephropathy) complications of DM [64, 66, 67].”
BackgroundExenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 112
“Its place in therapy was solidified with the landmark United Kingdom Prospective Diabetes Study (UKPDS).(8,9) In the UKPDS, overweight patients with newly diagnosed T2DM were randomized to an intensive glycemic control strategy with metformin versus conventional therapy with diet alone.”
BackgroundMethodFormononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
Oza, M. J., & Kulkarni, Y. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00739 · Cited by 133
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
Alicic, R. Z., Neumiller, J. J., Johnson, E. J., Dieter, B., & Tuttle, K. R. (2019) · Diabetes · doi:10.2337/dbi18-0007 · Cited by 121
“The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) (ClinicalTrials.org identifier NCT02065791) and A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With CKD (Dapa-CKD) (ClinicalTrials.org identifier NCT…”
BackgroundInfluentialPacker, M. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020010010 · Cited by 123
Gilbert, R. E., Huang, Q., Thai, K., Advani, S. L., Lee, K., Yuen, D. A., Connelly, K. A., & Advani, A. (2011) · Kidney International · doi:10.1038/ki.2011.39 · Cited by 127
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses
Lasserson, D. S., Glasziou, P., Perera, R., Holman, R. R., & Farmer, A. A. (2009) · Diabetologia · doi:10.1007/s00125-009-1468-7 · Cited by 131
“S te ho uw er , 20 03 [4 0] 26 1 49 .”
BackgroundInfluentialSelf-citationHigh-dose Insulin Therapy: is it Time for U-500 Insulin?
Lane, W. S., Cochran, E. K., Jackson, J. A., Scism-Bacon, J. L., Corey, I. B., Hirsch, I. B., & Skyler, J. S. (2009) · Endocrine Practice · doi:10.4158/ep.15.1.71 · Cited by 127
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
Hanefeld, M., Frier, B. M., & Pistrosch, F. (2016) · Diabetes Care · doi:10.2337/dcs15-3014 · Cited by 121
Baum, A., Scarpa, J., Bruzelius, E., Tamler, R., Basu, S., & Faghmous, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30176-6 · Cited by 120
Latres, E., Finan, D. A., Greenstein, J. L., Kowalski, A., & Kieffer, T. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.007 · Cited by 117
Huang, J., Ding, S., Xiong, S., & Liu, Z. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.730845 · Cited by 149
Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
Jia, G., Bai, H., Mather, B., Hill, M. A., Jia, G., & Sowers, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020804 · Cited by 135
“Epidemiological studies have demonstrated an 11% to 16% increase in CVD events for every 1% increase in HbA 1c [38,39].”
BackgroundHbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the Evidence.
Florkowski, C. M. (2013) · Europe PMC (PubMed Central) · Cited by 195
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 130
Effects of myostatin deletion in aging mice
Morissette, M. R., Stricker, J. C., Rosenberg, M. A., Buranasombati, C., Levitan, E. B., Mittleman, M. A., & Rosenzweig, A. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00508.x · Cited by 117
“…that improved glucose handling at a young age secondary to low RBP4 levels may provide a metabolic ‘memory’ or ‘legacy’ effect, similar to intensive glycemic control in type II diabetics that show benefits after long-term follow-up despite the cessation of intensive therapy (Holman et al., 2008).”
BackgroundA study of the natural history of diabetic kidney disease (DKD)
Altemtam, N., Russell, J., & Nahas, M. E. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr561 · Cited by 130
“This has been showed in 10 years follow-up UKPDS study in patients with T2DM as it did not demonstrate any risk reduction for myocardial infarction and death from any cause [32].”
MethodRosenstock, J., Lorber, D. L., Gnudi, L., Howard, C. P., Bilheimer, D. W., Chang, P.-C., Petrucci, R., Boss, A., & Richardson, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60632-0 · Cited by 122
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 112
“Its place in therapy was solidified with the landmark United Kingdom Prospective Diabetes Study (UKPDS).(8,9) In the UKPDS, overweight patients with newly diagnosed T2DM were randomized to an intensive glycemic control strategy with metformin versus conventional therapy with diet alone.”
BackgroundMethodDietary Flavonoids in the Prevention of T2D: An Overview
Alkhalidy, H., Wang, Y., & Liu, D. (2018) · Nutrients · doi:10.3390/nu10040438 · Cited by 143
“The type and starting time of treatment upon diagnosis was associated with the risk of developing the complications [17,19].”
BackgroundDiabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
“Additional follow-up for 8 to 10 years when all patients received intensive therapy found that the reduced risk of MI and mortality with initial metformin therapy persisted over time compared with early treatment using a sulfonylurea or insulin (15).”
ResultNew Drugs for Type 2 Diabetes Mellitus: What is their Place in Therapy?
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 142
“shown in the UKPDS, better glycaemic control pro- glycaemic control reduces vascular events many vides protection against the development of years later.[205] It is also noteworthy that the benefits”
InfluentialDiabetes mellitus correlates with increased biological age as indicated by clinical biomarkers
Bahour, N., Cortez, B., Pan, H., Shah, H., Doria, A., & Aguayo-Mazzucato, C. (2022) · GeroScience · doi:10.1007/s11357-021-00469-0 · Cited by 121
“For example, evidence has shown that premature aging in T2D leads to an increased risk of cardiomyopathy [27] and our study found a high correlation between age ratio and systolic blood pressure, which promotes myocardial remodeling and is a risk factor in the development of cardiomyopathy [28, 29].”
BackgroundMethodGlycemic Control and Cardiovascular Events in Diabetic Hemodialysis Patients
Drechsler, C., Krane, V., Ritz, E., März, W., & Wanner, C. (2009) · Circulation · doi:10.1161/circulationaha.109.857268 · Cited by 131
“QT interval, corrected, ms 423 (39) 427 (39) 426 (39)”
Telehealth Practice Recommendations for Diabetic Retinopathy, Second Edition
Li, H. K., Horton, M., Bursell, S.-E., Cavallerano, J., Zimmer-Galler, I., Tennant, M., Abramoff, M., Chaum, E., DeBuc, D. C., Leonard-Martin, T., et al. (2011) · Telemedicine and e-Health · doi:10.1089/tmj.2011.0075 · Cited by 121
Kaul, S., Bolger, A. F., Herrington, D., Giugliano, R. P., & Eckel, R. H. (2010) · Circulation · doi:10.1161/cir.0b013e3181d34114 · Cited by 117
Natarajan, R. D. (2021) · Diabetes · doi:10.2337/dbi20-0030 · Cited by 135
“Similar benefits have also been observed in the Pittsburgh Epidemiology of Diabetes Complications Study of T1D patients (38) and the UK Prospective Diabetes Study (UKPDS) of T2D patients (termed “legacy effect”) (39).”
ResultAdler, A., Erqou, S. A., Lima, T. A. S., & Robinson, A. H. N. (2010) · Diabetologia · doi:10.1007/s00125-009-1638-7 · Cited by 133
“The (DCCT) did not report the effect of glycaemic control on LEA [40] and the UKPDS showed no significant risk reduction associated with randomisation to intensive blood glucose lowering either during the main trial or afterwards [3, 9, 16].”
BackgroundAquilante, C. L. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.154 · Cited by 139
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
“Tight glycemic control has been shown to reduce the risk of complications, yet this is not easily achieved or maintained (2).”
BackgroundDiabetes mellitus and other disorders of metabolism
(2009) · Elsevier eBooks · doi:10.1016/b978-0-7020-2993-6.00024-9 · Cited by 122
Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
Smulders, Y. M., & Blom, H. J. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9151-1 · Cited by 131
“The importance of this final assumption cannot be understated.”
BackgroundDiabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial
Gerstein, H. C., Ambrosius, W. T., Danis, R., Ismail-Beigi, F., Cushman, W., Calles, J., Banerji, M., Schubart, U., Chew, E. Y., & for the ACCORD Study Group (2013) · Diabetes Care · doi:10.2337/dc12-1311 · Cited by 120
“Indeed, the findings of both the Diabetes Control and Complications Trial (in patients with type 1 diabetes) (18,19) and the UK Prospective Diabetes Study (in patients with type 2 diabetes) (20) that therapies that reduce the progression of retinal disease in the short-term subsequently reduce CV outcomes after long-t…”
ResultOellgaard, J., Gæde, P., Rossing, P. R., Persson, F., Parving, H., & Pedersen, O. B. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.023 · Cited by 124
Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
AADE Guidelines for the Practice of Diabetes Self-Management Education and Training (DSME/T)
American Association of Diabetes Educators (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721709352436 · Cited by 146
SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory
Paneni, F., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Diabetes · doi:10.2337/db12-1648 · Cited by 118
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
Haas, B., Eckstein, N., Pfeifer, V, Mayer, P., & Hass, M. D. S. (2014) · Nutrition & Diabetes · doi:10.1038/nutd.2014.40 · Cited by 113
Diabetes Induces Aberrant DNA Methylation in the Proximal Tubules of the Kidney
Marumo, T., Yagi, S., Kawarazaki, W., Nishimoto, M., Ayuzawa, N., Watanabe, A., Ueda, K., Hirahashi, J., Hishikawa, K., Sakurai, H., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070665 · Cited by 118
Wild, S. H., Hanley, J., Lewis, S. C., McKnight, J. A., McCloughan, L. B., Padfield, P. L., Parker, R. A., Paterson, M., Pinnock, H., Sheikh, A., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002098 · Cited by 115
“Control of blood glucose and blood pressure and management of dyslipidemia reduces complications and mortality among people with diabetes [2,3].”
BackgroundACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial
for the Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes (ACCORDION MIND) Investigators, Murray, A. M., Hsu, F.-C., Williamson, J. D., Bryan, R. N., Gerstein, H. C., Sullivan, M. D., Miller, M. E., Leng, I., Lovato, L. L., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4118-x · Cited by 117
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 110
Lipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 129
“A later benefit was observed if tight glucose control is initiated early in the course of disease in T1D patients [45], and in newly diagnosed T2D [46].”
BackgroundContinuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“The majority of studies of CGM in T2DM have shown that the use of this technology reduces HbA 1c , which is an accepted marker of micro-vascular complications and long-term macrovascular disease 7,8,84 .”
The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes
Pintaudi, B., Di Vieste, G., & Bonomo, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9132052 · Cited by 117
“Aim of our study was to evaluate the effectiveness and safety of myo-inositol and dchiro-inositol treatment in T2DM.”
BackgroundPradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., & Ridker, P. M. (2009) · JAMA · doi:10.1001/jama.2009.1347 · Cited by 117
Rise and fall of anti-obesity drugs
Li, M.-F. (2011) · World Journal of Diabetes · doi:10.4239/wjd.v2.i2.19 · Cited by 117
Lager, C. J., Esfandiari, N. H., Subauste, A. R., Kraftson, A. T., Brown, M. B., Cassidy, R. B., Nay, C. K., Lockwood, A. L., Varban, O. A., & Oral, E. A. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2265-2 · Cited by 109
“Even if the gap of metabolic control and weight loss eventually closes, it is possible to observe a Blegacy^ effect of a favorable state, the so-called metabolic memory, which may translate into meaningful outcomes as has been observed from UKPDS or DCCT/EDIC [39, 40].”
ResultPalta, P., Huang, E. S., Kalyani, R. R., Golden, S. H., & Yeh, H.-C. (2017) · Diabetes Care · doi:10.2337/dci16-0042 · Cited by 116
“these and other trials have also shown benefits with respect to cardiovascular events and mortality (6,7).”
BackgroundA Unified Pathophysiological Construct of Diabetes and its Complications
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., Aguilar, R. B., & Herman, M. E. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.005 · Cited by 127
Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis
Alqudah, A., McKinley, M. C., McNally, R., Graham, U., Watson, C. J., Lyons, T. J., & McClements, L. (2018) · Diabetic Medicine · doi:10.1111/dme.13523 · Cited by 114
Weinstein, G., Davis‐Plourde, K. L., Conner, S. C., Himali, J. J., Beiser, A., Lee, A., Rawlings, A. M., Sedaghat, S., Ding, J., Moshier, E. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212293 · Cited by 124
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 124
Tight Glycemic Control With Insulin in Hyperglycemic Preterm Babies: A Randomized Controlled Trial
Alsweiler, J. M., Harding, J. E., & Bloomfield, F. H. (2012) · PEDIATRICS · doi:10.1542/peds.2011-2470 · Cited by 126
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus
Strain, W. D., Cos, X., Hirst, M., Vencio, S., Mohan, V., Vokó, Z., Yabe, D., Blüher, M., & Paldánius, P. M. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.05.005 · Cited by 113
Liu, D., Li, X., Zhang, Y., Kwong, J. S. W., Li, L., Zhang, Y., Xu, C., Li, Q., Sun, X., Tian, H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166893 · Cited by 120
“blood pressure (25% reduction in Systolic Blood Pressure Intervention Trial [SPRINT] study) or glucose control (33% reduction in the United Kingdom Prospective Diabetes Study [UKPDS] study) in large clinical trials and of clinical significance.(38,39) Our study provides more favorable evidence of the preventive effect…”
Demaré, S., Kothari, A., Calcutt, N. A., & Fernyhough, P. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1847645 · Cited by 126
Bu, Y., Peng, M., Tang, X., Xu, X., Wu, Y., Chen, A. F., & Yang, X. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17519 · Cited by 127
Katz, R., Budoff, M. J., Takasu, J., Shavelle, D. M., Bertoni, A., Blumenthal, R. S., Ouyang, P., Wong, N. D., & O'Brien, K. D. (2009) · Diabetes · doi:10.2337/db08-1515 · Cited by 112
“001 Men 1,601 (49) 716 (43) 406 (53) 0.”
BackgroundAre dietary recommendations for the use of fish oils sustainable?
Jenkins, D. J. A., Sievenpiper, J. L., Pauly, D., Sumaila, U. R., Kendall, C. W. C., & Mowat, F. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081274 · Cited by 115
“Although this follow-up assessment of the DART results is largely criticized,(20) the same criticisms have not been raised in analogous situations, such as the United Kingdom Diabetes Prospective Study, in which a significant benefit of glycemic control was seen only after the end of the trial.(21) The influential Pre…”
ResultWright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0069 · Cited by 115
Effects of Dapagliflozin on Cardiovascular Risk Factors
Ptaszynska, A., Hardy, E., Johnsson, E., Parikh, S., & List, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2667 · Cited by 114
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach
Pozzilli, P., David Leslie, R., Chan, J., De Fronzo, R., Monnier, L., Raz, I., & Del Prato, S. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1092 · Cited by 114
“Early strict glycaemic control prevents micro- and macrovascular complications [7].”
BackgroundDing, S.-A., Simonson, D. C., Wewalka, M., Halperin, F., Foster, K., Goebel-Fabbri, A., Hamdy, O., Clancy, K., Lautz, D., Vernon, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1443 · Cited by 113
Mauricio, D., Meneghini, L., Seufert, J., Liao, L., Wang, H., Tong, L., Cali, A., Stella, P., Carita, P., & Khunti, K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12927 · Cited by 115
“The overarching goal of diabetes management is to reduce the risk of acute and chronic complications associated with the disease, in part, through appropriate glycaemic control.(1,2) The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) jointly recommend an evidence-based ge…”
BackgroundDavis, T. M. E., Coleman, R. L., & Holman, R. R. (2013) · Circulation · doi:10.1161/circulationaha.112.000908 · Cited by 128
“The 3277 surviving patients then entered a 10 year posttrial monitoring period in a usual-care setting.(11) They were seen annually for 5 years in UKPDS clinics with 3-year clinical examinations and continued standardized collection of predefined outcomes and other data.”
MethodSelf-citationRama Chandran, S., Tay, W. L., Lye, W. K., Lim, L. L., Ratnasingam, J., Tan, A. T. B., & S.L. Gardner, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0388 · Cited by 114
“5 While treating hyperglycemia clearly reduces the risk of micro-andmacrovascularcomplicationsinbothtype1andtype 2 diabetes, 6–9 the risk of hypoglycemia increases as HbA1c approaches target levels.”
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Current controversies in the use of haemoglobin A1c
Hare, M. J. L., Shaw, J. E., & Zimmet, P. Z. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02513.x · Cited by 106
Kalra, S., Aamir, A., Raza, A., Das, A., Azad Khan, A., Shrestha, D., Qureshi, M. F., Fariduddin, M., Pathan, M. F., Jawad, F., et al. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163171 · Cited by 111
“[26] This benefit persisted for up to 10 years in patients who had attained better glycaemic control.[60] Similar results were observed from 15 well designed long term (≥72‐weeks) RCTs, including ADOPT, ADVANCE[52] and ADVANCE‐ON,[61] where treatment with SUs was not found to be associated with an increase in CVD risk…”
Nauck, M. A., Del Prato, S., Durán‐García, S., Rohwedder, K., Langkilde, A. M., Sugg, J., & Parikh, S. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 113
“The lack of durable glycaemic efficacy, weight gain and hypoglycaemic risk associated with sulfonylurea therapy may explain why sulfonylureas are being used less today than in previous decades [27]; however, their low generic cost, together with trial data attesting to some long-term benefits [28,29], contributes to t…”
BackgroundCooper, G. J. S. (2011) · Drugs · doi:10.2165/11591370-000000000-00000 · Cited by 122
Khunti, K., Damci, T., Meneghini, L., Pan, C. Y., Yale, J. ‐., & on behalf of the SOLVE Study Group (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01602.x · Cited by 114
“The results of an analysis of the 10-year follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) suggest that patients receiving initial intensive treatment do have reductions in cardiovascular- and all-cause mortality [18].”
O'Reilly, M. W., Avalos, G., Dennedy, M. C., O'Sullivan, E. P., & Dunne, F. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0663 · Cited by 109
Roche, M. M., & Wang, P. P. (2013) · Diabetes Care · doi:10.2337/dc12-1272 · Cited by 113
“The authors used the term “legacy effect” to describe the continued benefit of intensive treatment (38).”
MethodImran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Alva, M., Gray, A., Mihaylova, B., & Clarke, P. (2014) · Health Economics · doi:10.1002/hec.2930 · Cited by 109
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 118
Raskin, P., Gylvin, T., Weng, W., & Chaykin, L. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.989 · Cited by 113
Derosa, G., Maffioli, P., SALVADEO, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.10.007 · Cited by 120
Kishi, S., Gidding, S. S., Reis, J. P., Colangelo, L. A., Ambale‐Venkatesh, B., Armstrong, A. D. C., Isogawa, A., Lewis, C. E., Wu, C. O., Jacobs, D. R., et al. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.02.033 · Cited by 123
“On the other hand, the UK Prospective DM Study enrolled patients with newonset DM and suggested a beneficial effect on CVD outcomes, including HF, during the 10 years of posttrial follow-up (30).”
BackgroundACE inhibitors and statins in adolescents with type 1 diabetes
Marcovecchio, M. L., Chiesa, S. T., Bond, S., Daneman, D., Dawson, S., Donaghue, K. C., Jones, T. W., Mahmud, F. H., Marshall, S. M., Neil, H. A. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703518 · Cited by 112
Self-citationDiabetic nephropathy: where are we on the journey from pathophysiology to treatment?
Gallagher, H., & Suckling, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12630 · Cited by 119
“This effect also operates in type 2 diabetes; long-term outcome data from the UK Prospective Diabetes Study show improved outcomes in participants initially assigned to intensive treatment evident after 10 years of follow-up, despite the loss of between-group differences in glycaemic control after the first year [34].”
BackgroundAli, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Shivashankar, R., Ajay, V. S., Unnikrishnan, A. G., Menon, V. U., Varthakavi, P. K., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2807 · Cited by 109
study, F. T. U., Shepherd, M. H., Shields, B. M., Hudson, M., Pearson, E. R., Hyde, C., Ellard, S., Hattersley, A. T., & Patel, K. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4728-6 · Cited by 109
Nidorf, S. M., Fiolet, A. T. L., Eikelboom, J. W., Schut, A., Opstal, T. S. J., Bax, W. A., Budgeon, C. A., Tijssen, J. G. P., Mosterd, A., Cornel, J. H., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.09.011 · Cited by 126
Webb, D. R., Khunti, K., Silverman, R., Gray, L. J., Srinivasan, B. T., Lacy, P. S., Williams, B., & Davies, M. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1689-9 · Cited by 123
Doyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., & Trujillo, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2470 · Cited by 111
“It may reduce the risk for cardiovascular events and death in persons who are overweight or obese (1).”
BackgroundWe Can Change the Natural History of Type 2 Diabetes
Phillips, L. S., Ratner, R. E., Buse, J. B., & Kahn, S. E. (2014) · Diabetes Care · doi:10.2337/dc14-0817 · Cited by 103
“Such relative stability of A1C levels was qualitatively different from the rise in A1C seen in the UK Prospective Diabetes Study (UKPDS) and in A Diabetes Outcome Progression Trial (ADOPT) (where glucose-lowering medications were administered in a fixed dosage, without titration) (41,44).”
BackgroundInfluentialColeman, K. J., Haneuse, S., Johnson, E., Bogart, A., Fisher, D., O’Connor, P. J., Sherwood, N. E., Sidney, S., Theis, M. K., Anau, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0194 · Cited by 107
Bassand, J., Accetta, G., Almahmeed, W. A., Corbalan, R. L., Eikelboom, J. W., Fitzmaurice, D. A., Fox, K. A. A., Gao, H., Goldhaber, S. Z., Goto, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191592 · Cited by 124
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.